“BUY PRIVATE – SELL PUBLIC – CAPTURE THE UPSIDE”

When companies move from being privately held to publicly traded, valuation accretion can immediately provide early investors an opportunity to profit from what is referred to as a “private to public valuation arbitrage.” It’s certainly not guaranteed, but it appears to happen the vast majority of times.

Public Company Valuations are Almost Always Higher than those for Private Companies

Private companies typically suffer from much lower valuations than do their public counterparts. This is because in addition to the same potential risks that public companies face, private company investments entail several significant drawbacks:

• Because there is no public market for shares in a private company, an investor who wishes to sell his or her share position must find a specific individual or group that may legally purchase their stock, and then do considerable legal paperwork to complete the sale.
• Because information about the business results and plans of a private company can be hard to come by, as they have no disclosure requirements and do not make filings with the SEC / U.S. Securities and Exchange Commission. This makes it difficult to correctly assess the likely fair value of private company shares.

Therefore, public company valuations can be and typically are 2 to 5 and sometimes, 10 times higher for public companies than for private ones, all other things being equal. In the Hyper-Growth, U.S. legal cannabis and medical marijuana industries,returns can be super-charged. The accreted value can happen in a period of several months to several years.

We believe that this, perhaps more than any other single factor, makes an investment in Pre IPO Private Cannabis Offerings, very attractive to would-be investors. And…in particular, we think you should take a close look at… this particular company.

Greenleaf Industries, Inc.

Greenleaf Industries is a rare opportunity for individuals to consider an investment in a Pre IPO Cannabis Company and possibly participate in a private to public company valuation arbitrage.

The Company is an early mover in the production, manufacture and distribution of high-grade CBD oil products derived from all-organic, full-spectrum, Colorado hemp extract.

Greenleaf has completed the formulation of multiple CBD oil infused product lines… actually, you could call them a “Cannabis Brands Company,” with an aspirationto be the Proctor & Gamble of cannabis.

The Company’s subsidiaries and multiple brands being developed include:

• Greenleaf Farms, Inc.:  providing over-the-counter and holistic healthcare solutions: its all-organic, full-spectrum CBD oil products have been sold on-line for over 2 ½ years;
• MediJaneRX: a pharmaceutical-grade medical brand focused on professional dispensary sales;
• PetMedic: an all-natural line of pet CBD oil medicinals being developed to support the daily health regimens for the 150 million dog and cat pets in the U.S.;
• Smiley STICK will be a brand focused on recreational sales;
• NeuroSport Pro is a professional strength line of pain, inflammation and neuro-protectant products the Company is developing for advanced injury protocols. NeuroSport Pro will include a full line of hemp-based nutritional and sports recovery supplements.

Greenleaf has developed and owns all of the intellectual property for these brands, which are in different stages of sales, marketing and distribution.

Summary and Investment Opportunity

The Problem & Opportunity – even with 66% of the U.S. population favoring legalization, the cannabis industry still faces myriad moral, legal and marketing challenges and no clear-cut CBD oil brand winner has yet emerged. Greenleaf intends to fill that void.

Solution & Service – Greenleaf Industries has plans to be a world-renowned, Holistic Healthcare Solutions Company which researches, produces and distributes hemp-centric products that target and treat seven major categories of medical conditions including: pain, psychological, gastrointestinal, cancer, autoimmune, neurological and sleep disorders.

Macro Industry Growth Factors – the U.S. legal cannabis and medical marijuana industry is forecast to drive about $40 billion in economic output by 2021; estimates include 414,000 new jobs and $4 billion in tax receipts; the Compound Annual Growth Rate (CAGR) is estimated at 30.7% thru 2023. 33 states and D.C. have passed legislation permitting recreational or medical usage; 74% of U.S. supports a bill shielding legal marijuana states from federal prosecution; 93% favor legalization for medical marijuana.
Sources: Quinnipiac University Poll 4/2018,  Arcview Group 1/2018 and Gallup Poll 10/2018

Company’s Prime Directive – Greenleaf Industries is focused on building a world-wide integratedhealthcare organizationby creating holistic medical solutions and programs using emergingbiological products such ascannabinoid plant extracts.They intend to deliver these programsthrough managed agriculture processes,pharmaceutical production, physician education andfull-service distribution networks.

Multiple Revenue Streams – Greenleaf is positioned to earn revenue from the sales of products through doctors’ offices, pharmacies, on-line ecommerce and the existing dispensary network. They intend to leverage the high margins created by being a pharmaceutical-grade producer, distributor and retailer in the world’s fastest growing industry – medical and recreational cannabis.

Product Delivery Systems – Greenleaf’s proprietary delivery systems will be doctor-driven to ensure accurate dosing and optimized delivery based on individual patient needs. Their delivery systems will include: sublingual tincture & sprays, dissolvable film strips, bronchial inhalers, transdermal patches, oral soft gel caps, topical gels, lotions & creams, plus vape pens and pre-loaded concentrates.

Competitive Advantages:

• Domain Expertise: extensive experience in IPOs & Capital Markets
• Sector Specific: focus is on the U.S. legal cannabis sector
• High yields, low cost production
• Premium, organic full-spectrum Colorado-sourced products
• Proprietary media channels to promote brand awareness, product sales and financial communications for stock-market awareness; the Company’s Google-approved news sites have ~250,000 monthly investor & retail customer visits

Management Team and Advisors:

• Stanley R. Abbott, President & CEO
• LaRue Thornton, COO & in-house legal counsel
• Dr. Mohyddin Mirza, Science Advisor
• DR. Guy Mezger, Sports Medicine Advisor
• Jeremy Bigham, Operations Specialist

We had a chance to review the recently released, one page Greenleaf Corporate Profile which summarizes what the Company believes could be a tremendous Pre IPO investment opportunity and lists “Five Reasons to Invest in Greenleaf Industries TODAY…!

1. Pre-IPO investment opportunity focused on the hyper-growth U.S. legal cannabis industry.
2. Seasoned management team and advisors have extensive capital markets and public company experience and cannabis domain expertise.
3. Tested proprietary marketing models, which leverages the Company’s media assets, yield a 10 to 1 ROI / Return On Investment; each dollar spent generates $10 in retail sales. 
4. Greenleaf Industries, Inc. intends to complete an IPO / Initial Public Offering in FY2019; early investors could potentially share in a private to public company valuation arbitrage that might yield 5 to 15 to 25 times their investment. “No guarantees, but the potential is there.”
5. Defined liquidity path with successful FY2019 IPO – this means no long-term lock-up of minority investors in a private company waiting to be acquired; stock would be freely tradable.

HERE’S THE BOTTOM LINE

Greenleaf Industries, Inc. could be a ground floor investment opportunity with tremendous upside potential. It is a private cannabis-focused company positioned in the fastest growing industry in the U.S. and probably the entire world…the CDB oil, medical marijuana and hemp industries.

The Company had been raising capital in a Reg D private placement that offered investors an opportunity to convert their investment into common stock.  For Pre-IPO Capital Partners, they were offering a 50% Discount to Market on the first round of public financing.

So if the stock opened at $1.00, and you were in at $0.50, you could have an immediate upside potential of 100% or more.  And, we’re fairly sure they don’t intend to stop there…we think they fully intend to strive for a 5 to 10 to 25X increase from that $1.00 level. Contact the Company for up-to-date information about current capital raises.

Here’s the kicker…Greenleaf has been positioning itself to be public through an S1 Registration or a reverse merger into an already trading public company. Reverse mergers are also “event certain” strategies to take companies public. When the reverse is complete or the S1 is declared effective, the Company should be in position to begin trading on the OTC Markets. There is no guarantee that the Company will be public this year or ever, but that is their stated plan.

This is how Pre-IPO investors can profit from the “private to public valuation arbitrage.”

“BUY PRIVATE – SELL PUBLIC – CAPTURE THE UPSIDE”

Greenleaf Industries, Inc.
109 E. 17th Street, Suite 5581
Cheyenne, WY 82001-4543
Telephone: 307-633-9876
investor@greenleaf.industries
www.greenleaf.industries

Sources:
www.greenleaf.industries
Greenleaf Industries, Inc. Investor Presentation
Greenleaf Industries, Inc. Corporate Profile

---

Greenleaf Industries, Inc. is one of many private companies that is positioning itself to take advantage of the dynamic/fast growing, U.S. legal cannabis and medical marijuana industry. This challenge is to find the ones you’re interested in, analyze them properly and make an informed decision about investing in the company before it executes a successful initial public offering / IPO. This is how we think our readers can profit from the “private to public valuation arbitrage.” Green Leaf Investing intends to help our readers accomplish that objective.

Disclaimer and Disclosures: Green Leaf Investing, Green Leaf or GLI is a financial publisher and not a FINRA broker/dealer or investment adviser. Green Leaf is not registered with the SEC / U.S. Securities and Exchange Commission or any state securities regulatory agency. Readers, subscribers and web site visitors are responsible for individual investment decisions. All information contained in our newsletters or on our web site and in our blogs should be independently verified with the featured companies and readers should always conduct their own research and due diligence and engage professional investment advisers as they deem appropriate before making investment decisions. Please review our Terms and Conditions of Use, including without limitation all disclaimers of warranties and limitations on liability contained therein. Your use of this web site and any information contained herein or in our newsletters and blogs constitutes your agreement of same. GLI has not received any compensation from the subject company for this editorial coverage. However, in the interest of full-disclosure, Mike Casson (Casson), Managing Director of Digital Investment Marketing, LLC, the parent company of GLI has served as VP of Investor Relations for Greenleaf Industries, Inc. (GII). Casson has been engaged by GII to assist in its capital markets and financial communications strategies. As you will read many times on these pages, micro and small-cap investing involves inherent risks and investors should carefully research any company considered for investment. Micro and small-cap companies are usually early in their market cycle and vulnerable to significant price volatility and you could lose your entire investment. Staff members of GLI, and affiliates, may hold positions in investments mentioned herein and may buy or sell said positions at any time without further notice.  GLI and/or affiliates may from time to time derive their compensation from publishing, marketing research, corporate relations, consulting services and database marketing programs for client sponsors. Therefore, you should not consider this editorial as independent, unbiased coverage; rather, consider it as a conflict of interest. Past results are not necessarily indicative of future performance.